Therapy Areas: Oncology
Raidium introduces AI-powered oncology imaging workflow for US cancer centres
17 July 2026 - AI-native radiology company Raidium announced on Thursday the US launch of Raidium Read (R.Read), applying its AI-native imaging solution initially to oncology research centres.Raidium ...
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
17 July 2026 - Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and gastrointestinal oncology, announced on Thursday the breakthro...
Intensity Therapeutics restarts breast cancer Phase 2 clinical trial
16 July 2026 - Intensity Therapeutics Inc (Nasdaq:INTS), a late-stage clinical biotechnology company, announced on Wednesday that new patients have been administered INT230-6 in the INVINCIBLE-4 Study...
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
15 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that its Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA (pembroliz...
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
15 July 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Tuesday that a Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-su...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...